INTRODUCTION: United States Preventative Service Task Force guidelines recommended one-time HCV Ab screening for patients born between 1945-1965. Some states have implemented mandatory opt-out HCV screening. With new antiviral therapies that have up to 95% success rate, the goal is to direct patients to care and ultimately eradicate HCV. Accurate measurement of the prevalence of HCV, in each district is crucial to implementing strategies at targeted populations. New York is among 9 states that make up about half of the nation's HCV burden. We present the prevalence and demographics of HCV exposed individuals screened in a safety net hospital in Long Island, NY. METHODS: Data was analyzed from 1/1/2012 to 8/31/2019 for those that were born between 1945-65. Our EMR system gathered patient charts positive (+) for HCV Ab. Retrospective chart review was performed, reviewing demographics (age, gender, ethnicity), persons with intravenous drug (PWID) use, and HIV co-infected status. Basic statistical analysis was applied. RESULTS: There were a total of 21,722 patients from 1/1/2012 to 8/31/2019 born between 1945-65. Table 1 shows that 1,858 individuals were tested for HCV Ab and 109(5.9%) were found (+). 56(3.0%) patients had active infection demonstrated by detectable RNA. Table 2 shows the demographic characteristics of those (+) for HCV Ab. Within that cohort, 77(70.6%) were male, 32(29.4%) female, 58(53.2%) Caucasian, 37(33.9%) Black, and 6(5.5%) were Asian. There were 17(15.6%) PWID, 4(3.7%) with HIV co-infection, 5(4.6%) individuals who had previous treatment and 2(1.8%) achieved SVR. CONCLUSION: The prevalence of HCV Ab in those born between 1945-65 was estimated to be 5.9% at our institution, which is almost double the national average of 3.2%. Men were more likely to be exposed than women. It is possible that focused efforts, with appropriate allocation of resources, dedicated to HCV case finding and treatment, aimed at safety-net institutions, in states or regions where there is a high burden of HCV, may be an effective strategy for decreasing the population burden of HCV and its sequela.Table 1.: HCV Ab Screening for patients born between 1945 - 1965 during January 1, 2012 to August 31, 2019Table 2.: Demographic data of patients screened and found to have HCV Ab